IBOGF.US Universal Ibogaine Inc
- Market cap
- USD 31.3K
- P/E
- -
- P/B
- 0.16x
- ROE
- -351.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Apr 2025.
Is IBOGF.US undervalued?
Graham numberThe Graham number of Universal Ibogaine Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Universal Ibogaine Inc fundamental analysis
No fundamental analysis for Universal Ibogaine Inc yet.
Universal Ibogaine Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Universal Ibogaine Inc
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.
Full company profileUniversal Ibogaine Inc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to Apr 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Universal Ibogaine Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.07M | 1.03M | 2.33M | 2.00M |
| Gross Profit | - | - | - | 0.00 | 1.07M | - | - | - |
| Operating Income | 64.0K | -33.9K | 383.00 | -3.83M | 497K | -2.05M | -901K | -52.7K |
| EBITDA | 64.0K | -33.9K | 638.00 | -3.76M | -4.61M | -1.98M | -1.54M | - |
| Net Income | -408K | -98.1K | -118K | -3.87M | -10.5M | -2.39M | -2.05M | -956K |
| EPS | -0.04 | -0.01 | -0.01 | -0.03 | -0.06 | -0.01 | -0.01 | 0.00 |
| Balance Sheet | ||||||||
| Total Assets | 321K | 217K | 117K | 3.99M | 6.32M | 5.50M | 4.51M | 4.01M |
| Total Liabilities | 25.4K | 20.1K | 21.7K | 1.05M | 2.37M | 3.75M | 3.52M | 3.73M |
| Shareholders' Equity | 295K | 197K | 94.9K | 2.94M | 3.94M | 1.75M | 991K | 272K |
| Cash & Short-term Investments | 51.9K | 205K | 72.5K | 142K | 726K | 313K | 371K | 128K |
| Total Debt | - | - | - | 410K | 1.74M | - | - | 2.57M |
| Cash Flow | ||||||||
| Operating Cash Flow | -320K | -72.0K | -122K | -3.25M | -4.33M | -1.10M | -839K | -744K |
| Capital Expenditure | 0.00 | 357K | 1.53K | 95.7K | 95.7K | 360K | 78.6K | 1.41K |
| Free Cash Flow | -320K | -72.0K | -124K | -3.25M | -4.43M | -1.46M | -917K | -745K |
| Ratios | ||||||||
| ROE | -138.3% | -49.8% | -124.7% | -131.4% | -266.2% | -136.5% | -207.0% | -351.4% |
| ROA | -127.3% | -45.2% | -101.5% | -96.9% | -166.1% | -43.4% | -45.5% | -23.9% |
| Net Profit Margin | - | - | - | - | -980.2% | -232.1% | -88.0% | -47.8% |
| Debt to Equity | - | - | - | 0.14x | 0.44x | - | - | 9.45x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Universal Ibogaine Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 410K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Universal Ibogaine Inc
- Insiders 13.44%
- Institutions 0.00%
- Public & others 86.56%
- Shares outstanding 313M
- Free float 303M
Universal Ibogaine Inc company profile
- Company name
- Universal Ibogaine Inc
- Ticker
- IBOGF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- July
- Address
- 815 8th Avenue SW, Calgary, AB, Canada, T2P 3P2
- Phone
- 855-426-4246
- Website
- universalibogaine.com
About Universal Ibogaine Inc
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.
Universal Ibogaine Inc management
3- Mr. Nicholas Peter KarosCEO, Director of Capital Markets & Director
- Mr. Shayne NyquvestCo-Founder
- Cathy FernandesVP of Marketing & VP of Communications